Trackinsight Enterprise, a unified platform for institutional ETF research, analytics, and compliance, is now live. Explore Trackinsight Enterprise →

Help us improve your experience. Please confirm your investor type:

Compare ETFs Easily

The Ultimate ETF Comparison Tool - Try Now!

Analyze up to 5 ETFs side-by-side and gain instant insights on performance, fees, holdings, and more to make data-driven investment decisions.

FBT

First Trust NYSE Arca Biotechnology ETF

Passive ETFEquity
Not rated

The FBT Exchange Traded Fund (ETF) is provided by First Trust. It is built to track an index: NYSE Arca Biotechnology Index. This share class generates a stream of income by distributing dividends.

Advertisement

Advertisement

$46.83
-$0.97 (-2.03%) 3 days ago
6:00 PM 08/28/26 Open
1D price range
$46.83$46.83
52W price range
$29.75$47.73
YTD Perf.
+30.79%
YTD Flows
Annualized volatility
Fund AuM
€4.3M
Share class AuM
€4.3M
TTM Yield
Tracking Error
Tracking Difference
ISIN
CA33742D1050
TER
0.71%
Inception date
10/30/2014
Replication method
Dividend policy
Compare similar ETFs
API
PerformanceDec 31, 2025 - Aug 28, 2026
-10%0%10%20%30%JANMARMAYJUL
Flows
Join for free to unlock
Data as of 07/31/26
Healthcare
99.86%
Unavailable
0.14%
Latest FBT news

No content available for this fund

FAQ about FBT

FBT is a Passive ETF. This ETF provides exposure to Equally Weighted US Biotechnology Equities.
FBT tracks the NYSE Arca Biotechnology Total Return Index - USD, through a replication method.
FBT carries a total expense ratio (TER) of 0.71%, indicating the annual cost for holding the fund.
FBT was introduced to the market on October 30, 2014. It trades on Canada
First Trust NYSE Arca Biotechnology ETF, FBT, is provided by First Trust. Learn more about First Trust here.
FBT oversees €4.3M in assets as of August 28, 2026.
FBT follows a distributing dividend policy, meaning it pays out income to investors.
As of July 31, 2026, FBT has significant geographic allocations in USA, Switzerland and Germany.
As of July 31, 2026, FBT focuses largely on Healthcare.
As of July 31, 2026, FBT holds 30 positions in its portfolio, with 55.87% of assets concentrated in its top 15 holdings.
As of July 31, 2026, FBT top three holdings include Halozyme Therapeutics, Inc., Corcept Therapeutics, Inc. and Repligen Corp..
The base currency of FBT is CAD.
Data as of 07/31/26
Halozyme Therapeutics, Inc.
4.31%
Corcept Therapeutics, Inc.
4.08%
Repligen Corp.
3.87%
Regeneron Pharmaceuticals, Inc.
3.85%
BeOne Medicines Ltd.
3.83%
BioNTech SE
3.75%
Natera, Inc.
3.73%
Amgen, Inc.
3.70%
argenx SE
3.66%
NeoGenomics, Inc.
3.63%

Trackinsight
Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:
  • More fund data
  • Compare up to 3 funds
  • More screener filters
  • Edit screener columns from 100+ metrics
  • Watchlists for saving your research
  • Portfolio construction and analysis
  • Personal dashboard for live monitoring

Advertisement

Trackinsight

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy  |  Cookie policy  |    |  Terms of use  |  Imprint
Trackinsight